Large-Scale Proteomics Improve Risk Prediction for Type 2 Diabetes
Authors' conclusion
The Olink Explore-based 15-protein model enhanced the CDRS model performance most, and this promising prediction model should be externally validated. Our successful external validation of the Olink Inflammation panel-based six-protein model shows that this is a promising endeavor.
Study context
- Population
- UK Biobank participants (derivation and internal validation) and ESTHER cohort (Germany) participants (external validation)21,898 UK Biobank
- Comparison
- Cambridge Diabetes Risk Score (CDRS) extended with proteomic biomarkers vs CDRS alone
- Outcome
- Incremental predictive value for T2D risk added to CDRS (C-index, net reclassification)
- Follow-up
- 10-year
Methodological detailsinternal validation, external validation
- Internal validation
- External validation
Performance
As reported in the abstract
C-index improvement over CDRS (internal validation)
C-index improvement
0.029
CDRS + 15 proteins · net reclassification 23.0%
C-index improvement
0.016
CDRS + 6 proteins · net reclassification 29.0%
Further findings
External validation (ESTHER cohort): C-index improvement of the six-protein-extended model (Olink Inflammation panel) over the CDRS
- C-index improvement, six-protein-extended model vs CDRS, external validation
- 0.014
- External validation conducted only for the six-protein-extended model
Original publication
Large-Scale Proteomics Improve Risk Prediction for Type 2 Diabetes. Diabetes Care. Published 3 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →